ProCE Banner Activity

Phase III NALA: Neratinib + Capecitabine vs Lapatinib + Capecitabine in HER2+ MBC Previously Treated With HER2-Targeted Therapies

Slideset Download
Conference Coverage
Neratinib + capecitabine significantly prolonged PFS vs lapatinib + capecitabine (HR: 0.76) in patients with HER2+ MBC previously treated with at least 2 lines of therapy.

Released: June 07, 2019

Expiration: June 05, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro